Skip to content
Ipatasertib
Ipatasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-beta serine/threonine-protein kinase, RAC-gamma serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase. In addition, it is known to target cGMP-dependent protein kinase 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C507113——18
Prostatic neoplasmsD011471C61341——6
Triple negative breast neoplasmsD064726241——5
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8054———8
Ovarian neoplasmsD010051EFO_0003893C5623———5
Stomach neoplasmsD013274EFO_0003897C16—3———3
Non-small-cell lung carcinomaD00228913———3
Endometrial neoplasmsD016889EFO_000423012———2
Castration-resistant prostatic neoplasmsD06412921———2
Squamous cell carcinoma of head and neckD00007719511———2
Oropharyngeal neoplasmsD00995911———2
Laryngeal neoplasmsD007822EFO_0003817C3211———2
Hypopharyngeal neoplasmsD007012C1311———2
Show 21 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Hepatic insufficiencyD0485501————1
Squamous cell carcinomaD0022941————1
Fallopian tube neoplasmsD0051851————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIPATASERTIB
INNipatasertib
Description
(2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone is a N-arylpiperazine.
Classification
Small molecule
Drug classserine/threonine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1
Identifiers
PDB—
CAS-ID1001264-89-6
RxCUI—
ChEMBL IDCHEMBL2177390
ChEBI ID—
PubChem CID24788740
DrugBankDB11743
UNII ID524Y3IB4HQ (ChemIDplus, GSRS)
Target
Agency Approved
AKT2
AKT2
AKT3
AKT3
AKT1
AKT1
Organism
Homo sapiens
Gene name
AKT2
Gene synonyms
NCBI Gene ID
208
Protein name
RAC-beta serine/threonine-protein kinase
Protein synonyms
murine thymoma viral (v-akt) homolog-2, PKB beta, Protein kinase Akt-2, Protein kinase B beta, putative v-akt murine thymoma viral oncoprotein 2, rac protein kinase beta, RAC-PK-beta, v-akt murine thymoma viral oncogene homolog 2
Uniprot ID
P31751
Mouse ortholog
Akt2 (11652)
RAC-beta serine/threonine-protein kinase (Q60823)
Alternate
PRKG1
PRKG1
Organism
Homo sapiens
Gene name
PRKG1
Gene synonyms
PRKG1B, PRKGR1A, PRKGR1B
NCBI Gene ID
5592
Protein name
cGMP-dependent protein kinase 1
Protein synonyms
cGKI, cGMP-dependent protein kinase I, protein kinase, cGMP-dependent, regulatory, type I, beta, protein kinase, cGMP-dependent, type I
Uniprot ID
Q6P5T7
Mouse ortholog
Prkg1 (19091)
cGMP-dependent protein kinase 1 (Q9Z0Z0)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 941 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
89 adverse events reported
View more details